



David S. Perlin, Ph.D.

Chief Scientific Officer

Executive Vice President

Hackensack Meridian Health Center for Discovery and Innovation

Professor, Hackensack Meridian School of Medicine

Professor, Georgetown University School of Medicine

Fellow, New York Academy of Sciences

Fellow, American Academy of Microbiology

Fellow, Infectious Diseases Society of America

Dr. David S. Perlin is a highly accomplished biomedical researcher and chief executive who is well recognized for his innovative and entrepreneurial leadership in the biomedical sciences. He is the inaugural Chief Scientific Officer and EVP for the Hackensack Meridian **Center for Discovery and Innovation (CDI)**, which seeks to rapidly translate innovations in science to improve outcomes for patients with cancer, infectious diseases, autoimmune, and other acute and chronic disorders. Under his leadership, CDI has grown in less than five years to 33 laboratories with more than 200 scientists and support staff funded by 126 grants and contracts including 65 NIH grants. Dr. Perlin has been engaged for >30 years in developing molecular insights and technologies to detect, combat and prevent deadly infections. He is an expert in drug discovery and drug resistance mechanisms, and he has helped develop novel therapeutics and diagnostics against high-threat bacteria, viruses, and fungi. He has published more than 360 papers and book chapters and has co-authored two books, and his laboratory is supported by multiple grants from the NIH, Pharma and biopharma sectors, and the NIH has continuously funded him for 30+ years. He has served on numerous advisory boards for Pharma and Biotech to develop FDA approved drugs. Currently, he leads an NIH-designated national Center of Excellence in Translational Research (CETR) to discover novel anti-infectives against drug resistant bacterial infections. He recently co-led with Rockefeller University Nobel Laureate Dr. Charles Rice the Metropolitan Antiviral Drug Accelerator (MAVDA), one of nine national centers under the NIH AViDD program to develop novel small molecule antiviral drugs against SARS-CoV-2 and other pandemic viruses. Dr. Perlin was honored with a “*Medical Technology Pioneer Health Care Heroes*” award for COVID-19 response. He is a Fellow of the American Academy of Microbiology and the New York Academy of Sciences. Dr. Perlin was named by RO1 a top 10 influencer in healthcare in New Jersey in 2019 and 2020; an Outstanding Scientist in New Jersey by the Edward J. III Excellence in Medicine Awards in 2020, 2021, and in 2021, and a top 25 National Innovator by Modern Healthcare. He was named in 2022 a top 25 Notable Health Care Leader by *Crain’s New York Business*. He received the 2023 Dr. Sol J. Barer Award for Vision Innovation and Leadership and was named by RO1 a top 25 healthcare influencer in 2024.